Arcus Biosciences EBITDA 2017-2022 | RCUS

Arcus Biosciences ebitda from 2017 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Arcus Biosciences Annual EBITDA
(Millions of US $)
2021 $63
2020 $-121
2019 $-88
2018 $-53
2017 $-51
2016 $-17
Arcus Biosciences Quarterly EBITDA
(Millions of US $)
2022-03-31 $-64
2021-12-31 $283
2021-09-30 $-75
2021-06-30 $-73
2021-03-31 $-71
2020-12-31 $-51
2020-09-30 $3
2020-06-30 $-45
2020-03-31 $-28
2019-12-31 $-17
2019-09-30 $-23
2019-06-30 $-29
2019-03-31 $-19
2018-12-31 $-13
2018-09-30 $-12
2018-06-30 $-15
2018-03-31 $-13
2017-12-31 $-13
2017-09-30 $-22
2017-06-30 $-9
2017-03-31 $-7
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.792B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00